English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

WOODRUFF AND SYMES (1962) were able to retard the growth of mouse mammary carcinoma transplants, in isogenic hosts, by administration of sublethal whole body irradiation followed by injection of allogeneic immunologically competent cells. The irradiation was given to facilitate the survival of the injected cells which were obtained either from normal donors, or animals pre-immunized against the tumour to be treated. Pre-immunized cells were therapeutically more effective. The use of immunologically competent cells in the treatment of leukaemia transplants in isogenic mice has been reported by Alexander, Connell and Mikulska (1966). They found that it was possible to destroy tumours by treatment, two days after transplantation, using spleen cells from immunized allogeneic donors. However, it was necessary to inject spleen cells in a ratio of 200 to every 1 lymphoma cell, estimated to be present. It was hoped that after giving immunosuppressive therapy with Melphalan (L-phenylalanine mustard), as a prelude to allogeneic spleen cell injection, a lesser number of immunologically competent cells might suffice to produce a significant anti-tumour effect. If this were so it would be possible to treat lymphomata at correspondingly greater intervals after their transplantation.

british journal of cancer

Attempts to induce a graft-versus-tumour reaction against AKR lymphomata, in isogenic mice, by injection of Melphalan and foreign immunologically competent cells.